275 related articles for article (PubMed ID: 30578766)
1. An N
Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
[TBL] [Abstract][Full Text] [Related]
2. Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin-activated RNA methylation.
Roy KR; Uddin MB; Roy SC; Hill RA; Marshall J; Li YT; Chamcheu JC; Lu H; Liu YY
FASEB Bioadv; 2020 Nov; 2(11):653-667. PubMed ID: 33205006
[TBL] [Abstract][Full Text] [Related]
3. Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion.
Guo AK; Itahana Y; Seshachalam VP; Chow HY; Ghosh S; Itahana K
Br J Cancer; 2021 Jan; 124(1):299-312. PubMed ID: 33144694
[TBL] [Abstract][Full Text] [Related]
4. Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma.
Kang N; Wang Y; Guo S; Ou Y; Wang G; Chen J; Li D; Zhan Q
BMC Cell Biol; 2018 Aug; 19(1):16. PubMed ID: 30126368
[TBL] [Abstract][Full Text] [Related]
5. The Oncological Effect of Mutant p53 on the Metastatic Phenotype of Gastric Cancer Cells.
Kitagawa H; Hiraki M; Namba T; Baba K; Miyake S; Ito K; Tanaka T; Noshiro H
Anticancer Res; 2023 Nov; 43(11):4887-4895. PubMed ID: 37909947
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 in cancer therapy-the barrier or the path.
Zhou X; Hao Q; Lu H
J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
[TBL] [Abstract][Full Text] [Related]
7. N
Kuppers DA; Arora S; Lim Y; Lim AR; Carter LM; Corrin PD; Plaisier CL; Basom R; Delrow JJ; Wang S; Hansen He H; Torok-Storb B; Hsieh AC; Paddison PJ
Nat Commun; 2019 Oct; 10(1):4596. PubMed ID: 31601799
[TBL] [Abstract][Full Text] [Related]
8.
Coan M; Toso M; Cesaratto L; Rigo I; Borgna S; Dalla Pietà A; Zandonà L; Iuri L; Zucchetto A; Piazza C; Baldassarre G; Spizzo R; Nicoloso MS
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762037
[No Abstract] [Full Text] [Related]
9. Do Mutations Turn p53 into an Oncogene?
Pitolli C; Wang Y; Mancini M; Shi Y; Melino G; Amelio I
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835684
[TBL] [Abstract][Full Text] [Related]
10. Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?
Lim DV; Woo WH; Lim JX; Loh XY; Soh HT; Lim SYA; Lee ZY; Yow HY; Hamzah SB; Sellappans R; Foo JB
Curr Mol Pharmacol; 2024; 17(1):e140923221042. PubMed ID: 37711005
[TBL] [Abstract][Full Text] [Related]
11. Rewired m
Xu A; Liu M; Huang MF; Zhang Y; Hu R; Gingold JA; Liu Y; Zhu D; Chien CS; Wang WC; Liao Z; Yuan F; Hsu CW; Tu J; Yu Y; Rosen T; Xiong F; Jia P; Yang YP; Bazer DA; Chen YW; Li W; Huff CD; Zhu JJ; Aguilo F; Chiou SH; Boles NC; Lai CC; Hung MC; Zhao Z; Van Nostrand EL; Zhao R; Lee DF
Nat Commun; 2023 Mar; 14(1):1694. PubMed ID: 36973285
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications.
Oduah EI; Sharfstein ST; Seetharamu N; Grossman SR; Litovchick L
Front Oncol; 2024; 14():1363543. PubMed ID: 38660140
[TBL] [Abstract][Full Text] [Related]
13. Distinct functions of wild-type and R273H mutant Δ133p53α differentially regulate glioblastoma aggressiveness and therapy-induced senescence.
Harris C; Joruiz S; Von Muhlinen N; Horikawa I; Gilbert M
Res Sq; 2023 Nov; ():. PubMed ID: 37986881
[TBL] [Abstract][Full Text] [Related]
14. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.
Ellison V; Annor GK; Freedman C; Xiao G; Lundine D; Freulich E; Prives C; Bargonetti J
Oncotarget; 2021 Jun; 12(12):1128-1146. PubMed ID: 34136083
[TBL] [Abstract][Full Text] [Related]
15. Nanoreceptors promote mutant p53 protein degradation by mimicking selective autophagy receptors.
Huang X; Cao Z; Qian J; Ding T; Wu Y; Zhang H; Zhong S; Wang X; Ren X; Zhang W; Xu Y; Yao G; Wang X; Yang X; Wen L; Zhang Y
Nat Nanotechnol; 2024 Apr; 19(4):545-553. PubMed ID: 38216684
[TBL] [Abstract][Full Text] [Related]
16. Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutants.
Pal A; Gonzalez-Malerva L; Eaton S; Xu C; Zhang Y; Grief D; Sakala L; Nwekwo L; Zeng J; Christensen G; Gupta C; Streitwieser E; Singharoy A; Park JG; LaBaer J
NPJ Breast Cancer; 2023 Sep; 9(1):78. PubMed ID: 37773066
[TBL] [Abstract][Full Text] [Related]
17. Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin.
Therachiyil L; Haroon J; Sahir F; Siveen KS; Uddin S; Kulinski M; Buddenkotte J; Steinhoff M; Krishnankutty R
Front Oncol; 2020; 10():1744. PubMed ID: 32984059
[TBL] [Abstract][Full Text] [Related]
18. Single-Atom Catalysts Mediated Bioorthogonal Modulation of N
Sun M; Liu X; Liu Z; Zhang W; Li G; Ren J; Qu X
J Am Chem Soc; 2024 Mar; 146(12):8216-8227. PubMed ID: 38486429
[TBL] [Abstract][Full Text] [Related]
19. Disrupting the interaction between a p53 gain-of-function mutant and the transcriptional co-activator PC4 reverses drug resistance in cancer cells.
Mondal P; Roy KS; Bhagat SV; Singh S; Chattopadhyay A; Ghosh DD; Kundu TK; Roychoudhury S; Roy S
FEBS Lett; 2024 Apr; ():. PubMed ID: 38664232
[TBL] [Abstract][Full Text] [Related]
20. MAPK13 stabilization via m
Kim J; Chun Y; Ramirez CB; Hoffner LA; Jung S; Jang KH; Rubtsova VI; Jang C; Lee G
J Biol Chem; 2023 Sep; 299(9):105175. PubMed ID: 37599001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
